Alzheimer’s

Biotech Adam Feuerstein

STAT Plus: Biogen’s tau-lowering drug slows cognitive decline in early study of Alzheimer’s disease

First Opinion Kristina Carvalho

Do dementia villages actually work? We just don’t know

Adam's Take Adam Feuerstein

STAT Plus: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials

Health Rachel Cohrs Zhang

STAT Plus: Medicare to cover more brain scans related to Alzheimer’s drugs

In the Lab Jonathan Wosen

STAT Plus: Scientists have mapped the human brain in unprecedented detail. They’re just getting started

Health Nicholas St. Fleur

How Seth Rogen and Lauren Miller Rogen are using comedy to support Alzheimer’s care

Pharmalot Ed Silverman and Rachel Cohrs Zhang

Policy experts call on Medicare to ensure data from Alzheimer’s drug registries is shared publicly

In the Lab Abdullahi Tsanni

These proteins could predict dementia risk decades before symptoms, new study suggests

Pharmalot Ed Silverman

STAT Plus: FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel

Health Kay Lazar — Boston Globe

STAT Plus: Cracking an intriguing secret of centenarians: Why so few are ravaged by Alzheimer’s disease

In the Lab Usha Lee McFarling

In the whitewashed world of Alzheimer’s research, one scientist is on a quest to understand the diversity of brains

Biotech Adam Feuerstein

STAT Plus: FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease

The Aduhelm Files Damian Garde and Rachel Cohrs Zhang

STAT Plus: In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments

The Aduhelm Files Rachel Cohrs Zhang, Adam Feuerstein, and Damian Garde

STAT Plus: FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation

The Aduhelm Files Rachel Cohrs Zhang

STAT Plus: ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol

The Aduhelm Files Damian Garde and Adam Feuerstein

STAT Plus: Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds

Biotech Jason Mast

STAT Plus: For Swedish professor and his tiny biotech, Alzheimer’s drug means vindication and a fortune

In the Lab Angus Chen

STAT Plus: Mutations tied to blood cancers and other diseases may surprisingly protect against Alzheimer’s

In the Lab Megan Molteni

STAT Plus: In the blood of marathoning mice, scientists find clues to how exercise benefits the brain

Biotech Adam Feuerstein and Damian Garde

STAT Plus: European regulators signal Biogen’s new Alzheimer’s therapy is unlikely to win approval

Biotech Damian Garde

STAT Plus: Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial

Biotech Adam Feuerstein

STAT Plus: ‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment

Biotech Adam Feuerstein

STAT Plus: Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions

In the Lab Megan Molteni

Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment

Biotech Adam Feuerstein

STAT Plus: Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

Adam's Take Adam Feuerstein

STAT Plus: In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s

Pharma Adam Feuerstein

STAT Plus: In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment

Biotech Matthew Herper, Damian Garde, and Adam Feuerstein

Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm

Health Andrew Joseph

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision